Abstract
Novel NO-donor-caffeic acid hybrids with antioxidant, nitric oxide release and vasodilator properties were designed and synthesized through a symbiotic approach using caffeic acid and three different NO-donating groups such as nitric ester, 4-hydroxyl-3-phenylfuroxan and 4-hydroxymethyl-3-phenylsulfonylfuroxan. The antioxidant activities of these hybrid products were assessed by DPPH assay and by detecting the TBARS produced in the ferrous salt/ascorbate induced autoxidation of lipids which were present in microsomial membranes of rat hepatocytes. The nitric oxide release activities were assessed by indirect evaluation of the produced nitrite. The vasodilator activities were determined through an in vitro vascular relaxation assay (organ bath) using PGF2α-precontracted porcine pulmonary arteries. The results showed that the target phenylsulfonylfuroxan 12, especially 12a while keeping the antioxidant activity, showed more NO release activity and vasodilating activity than isosorbide dinitrate (ISDN). Thus 12a may be considered as a novel potent anti-atherosclerosiss drug candidate.
Keywords: Atherosclerosis, Nitric oxide donor, Caffeic acid, Antioxidant activity, Nitric oxide release, Vasodilator activity, LDL, Acid Hybrids, Anti-Atherosclerotic, Moiety, reactive oxygen species (ROS), vasodilation, isoproterenol (ISO), myocardial infarction, dibromoalkanes, lipid autooxidation
Letters in Drug Design & Discovery
Title: Design, Synthesis and Biological Study of Novel NO-Donor-Caffeic Acid Hybrids as Potential Anti-Atherosclerotic Drug Candidates
Volume: 8 Issue: 6
Author(s): Nian-Guang Li, Rong Wang, Yu-Ping Tang, Zhi-Hao Shi, Bao-Quan Li, Wei Li, Jian-Ping Yang, Zhen-Jiang Wang, Shu-Lin Song, Li-Hua Qian, Li-Juan Yao, Jun-Zuan Xia, Jia Xu, Feng Feng, Da-Wei Qian and Jin-Ao Duan
Affiliation:
Keywords: Atherosclerosis, Nitric oxide donor, Caffeic acid, Antioxidant activity, Nitric oxide release, Vasodilator activity, LDL, Acid Hybrids, Anti-Atherosclerotic, Moiety, reactive oxygen species (ROS), vasodilation, isoproterenol (ISO), myocardial infarction, dibromoalkanes, lipid autooxidation
Abstract: Novel NO-donor-caffeic acid hybrids with antioxidant, nitric oxide release and vasodilator properties were designed and synthesized through a symbiotic approach using caffeic acid and three different NO-donating groups such as nitric ester, 4-hydroxyl-3-phenylfuroxan and 4-hydroxymethyl-3-phenylsulfonylfuroxan. The antioxidant activities of these hybrid products were assessed by DPPH assay and by detecting the TBARS produced in the ferrous salt/ascorbate induced autoxidation of lipids which were present in microsomial membranes of rat hepatocytes. The nitric oxide release activities were assessed by indirect evaluation of the produced nitrite. The vasodilator activities were determined through an in vitro vascular relaxation assay (organ bath) using PGF2α-precontracted porcine pulmonary arteries. The results showed that the target phenylsulfonylfuroxan 12, especially 12a while keeping the antioxidant activity, showed more NO release activity and vasodilating activity than isosorbide dinitrate (ISDN). Thus 12a may be considered as a novel potent anti-atherosclerosiss drug candidate.
Export Options
About this article
Cite this article as:
Li Nian-Guang, Wang Rong, Tang Yu-Ping, Shi Zhi-Hao, Li Bao-Quan, Li Wei, Yang Jian-Ping, Wang Zhen-Jiang, Song Shu-Lin, Qian Li-Hua, Yao Li-Juan, Xia Jun-Zuan, Xu Jia, Feng Feng, Qian Da-Wei and Duan Jin-Ao, Design, Synthesis and Biological Study of Novel NO-Donor-Caffeic Acid Hybrids as Potential Anti-Atherosclerotic Drug Candidates, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906848
DOI https://dx.doi.org/10.2174/157018011795906848 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of a New Class of Compounds of the Group of Substituted 5R1, 6H2-1,3,4-thiadiazine-2-amines on the Inflammatory and Cytokine Response in Experimental Myocardial Infarction
Current Vascular Pharmacology Vascular Progenitor Cells in the Development of Transplant Arteriopathy
Current Genomics Adult Neurogenic and Antidepressant Effects of Adiponectin: A Potential Replacement for Exercise
CNS & Neurological Disorders - Drug Targets Protective Effects of Corticosteroids and Neurosteroids on Cochlear injury
Medicinal Chemistry Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Overlap Syndrome of Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea: A Two-Faced Janus
Current Respiratory Medicine Reviews Targets Involved in Cardioprotection by the Non-Anesthetic Noble Gas Helium
Current Drug Targets Admission, 24 Hours and Discharge Troponin T Among Acute Myocardial Infarction Patients: Differing by Prognostic Contribution
Recent Patents on Biomarkers Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism Proteome and Metabolome Alterations in Heart and Liver Indicate Compromised Energy Production During Sepsis
Protein & Peptide Letters Commentary-1 Research Highlights (Never Underestimate the Power of Adenosine in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets Editorial [ Proteases and Phospholipases in CNS Disorders Guest Editor: Swapan K. Ray ]
CNS & Neurological Disorders - Drug Targets Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Heat Shock Protein-60 and Risk for Cardiovascular Disease
Current Pharmaceutical Design Computational Insights into the Role of Glutathione in Oxidative Stress
Current Neurovascular Research Editorial: Statins and Tissue Plasminogen Activator for Stroke: A Beneficial Combination?
Current Vascular Pharmacology Vascular effects of flavonoids
Current Medicinal Chemistry Pexelizumab, an Anti-C5 Complement Antibody for Primary Coronary Revascularization: A New Insight from Old Versions
Cardiovascular & Hematological Disorders-Drug Targets Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation
Current Drug Targets Recent Development of Hydrogen Sulfide Therapeutics in the Treatment of Cardiovascular Diseases
Current Topics in Medicinal Chemistry